Combinatorial therapy for Deafness: A therapeutic mix encompassing 4-Phenylbutyrate (4-PBA), Cholecalciferol, Ajoene and DIM (PCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via upregulation of its target genes, 28/February/2019, 8.00 am

Combinatorial anti-cancer therapy targeting CDK4/6 pathway and immune receptors enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing  Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG)  inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 28/February/2019, 7.39 am
February 28, 2019
Probiotics function as anti-HIV agents: Probiotic Bacillus subtilis B10 increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene, 28/February/2019, 8.09 am
February 28, 2019
Show all

National Science day special

*********

We wish everyone a very happy national science day. On this special occasion, we are happy to announce that Bio-Med/Pharma/Therapeutic/Clinical ideas posted today (28/February/2019) will be available to the use of Scientists/Professors/Faculties/Teachers/Physicians/Researchers for free. So, there will be no terms and conditions for the ideas posted today. Each idea posted will be served first come, first serve basis. Write to admin@genomediscovery.org for more details.

Dr L Boominathan PhD

President, Director & CSO, GBMD.

_________________________________________________________________________________________________________________________________________________

 

What we say:

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial therapy for Deafness: A therapeutic mix encompassing 4-Phenylbutyrate (4-PBA), Cholecalciferol, Ajoene and DIM (PCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via upregulation of its target genes

[easy_payment currency=”USD”]


From Significance of the study to Public health relevance:

Given that: (1) more than one-seventh of the global population suffers from hearing impairment;  (2) the majority of hearing impairment occurs in  low and middle-income countries, for instance, 3 in 1000 from developed countries, while 6 in 1000 from developing countries suffer from hearing impairment; (3) damage to the auditory hair cells (HCs) is the principal reason for hearing loss;  (4) only in 50% cases hearing impairment can be cured; and (5) the global annual economic cost spent for unaddressed hearing loss is estimated to be in the range of $750–790 billion, there is an urgent need to find: (i) a way to promote regeneration, growth, and proliferation of auditory hair cells  in mammalian cochlea; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, hearing impairment.


From research findings to Therapeutic opportunity: 

This study provides, for the first time, mechanistic insights into how a pharmaceutical mixture encompassing 4-Phenylbutyrate (4-PBA), Cholecalciferol, Ajoene and DIM (PCAD)  may aid in the treatment of hearing impairment.

PCAD, by increasing the expression of its target genes, it may increase the expression of longevity-promoting gene ATG5 (Autophagy-related protein 5). Thereby, it may: (1) prevent degeneration of adult hair cells; (2) prevent aggregation of polyubiquitinated proteins and p62/SQSTM1 in inclusion bodies; (3) promote maintenance of hair cells morphology and hearing acuity; and (4) prevent hearing loss. Thus, pharmacological mixture encompassing “4-Phenylbutyrate (4-PBA), Cholecalciferol, Ajoene and DIM (PCAD) or their analogseither alone or in combination with other drugs, may be used to treat deafness (Fig.1).

Figure 1 Mechanistic insights into how a therapeutic mix encompassing 4-Phenylbutyrate (4-PBA), Cholecalciferol, Ajoene and DIM (PCAD) aids in improving hearing impairment. FCAD prevents aggregation of proteins, promotes regeneration of adult hair cells and inhibits hearing impairment via up-regulation of its target gene ATG5

Figure 2 4-Phenylbutyrate (4-PBA) prevents hearing loss through induction of ATG5

[easy_payment currency=”USD”]

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does a therapeutic mix encompassing 4-Phenylbutyrate (4-PBA), Cholecalciferol, Ajoene and DIM (PCAD)  increase the expression of ATG5?

Amount: $500#

For payment and purchase details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Combinatorial therapy for Deafness: A therapeutic mix encompassing 4-Phenylbutyrate (4-PBA), Cholecalciferol, Ajoene and DIM (PCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via upregulation of its target genes, 28/February/2019, 8.00 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at admin@genomediscovery.org

Comments are closed.